Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Much thanks for your reply. It came across as an INFORMED YES!!!!
BIG QUESTION BOLDLY ASKED!!!
DOES ANATABINE CITRATE WITH ITS IMPRESSIVE SAFETY PROFILE HAVE THE POTENTIAL TO BE A BREAKTHROUGH ANTI-INFLAMMATORY??????
THANK YOU! My mistaken impression was that anatabine modulated spleen tyrosine kinase, as does Nilvadapine.
seek
Please elaborate for our edification. Your curt reply seems to indicate you know for a fact that anatabine is not a part of the Archer/Roskamp/Alzheimer future effort.
A reading of the planning for commercializing Nilvadapine for the treatment of Alzheimer's demonstrates the seriousness of the NILVAD project and describes its intention to proceed with 2nd generation meds developed by Archer, which I believe includes anatabine.
http://www.nilvad.eu/the-project/wp08-exploitation-and-scientific-direction/
Sooo hard to believe that there isn't a pharma in the entire world that would have signed on to an exclusive license for an anatabine ointment/cream that could treat mild to moderate psoriasis. It could be structured with a very low, or even no royalties in exchange for significant upfront cash payments based on achieving specified milestones.
What the heck is going on here!
Luther
There is much more to the story than gets discussed here. Dr. Mullan is also the CEO and CSO of Archer Pharmaceutical which holds the patent rights on Nilvadipine as a treatment for Alzheimers. I fully expect that in about 6 months,he will be announcing the first ever significant breakthrough in the treatment of Alzheimers using Nilvadipine.
He also is in charge of Exploitation and Scientific Direction in seeking drug approval of Nilvadipine as a treatment for Alzheimers.
I believe that anatabine is at least equal to , if not better than Nilvadipine in its ability to impact Alzheimers. Given Dr. Mullan's connection to RCPI, Archer, and The Nilvad Project which is about to wind up its multi-year, 500+ patient Nilvadipine/Alzheimers study, we have an interesting situation, and, yet, RCPI trades at 5 mills. SIGH!
COSMIC IS RIGHT! For 5 years now there has been a TOTAL disconnect between the discovery of anatabine's ability to knock down chronic inflammation harmlessly, and the medical media and industry totally ignoring what appears to be a breakthrough discovery. Also, Wall Street is acting like the discovery is totally worthless.
What the heck am I missing here!!!!!!!!!!!!!!!!!!
After the message posted I tried the link and it worked. Now I see it doesn't.
After the message posted I tried the link and it worked. Now I see it doesn't.
You can google "Japanese patent # 2014-528385
Click on "Search Japanese patents in English"
Then click the link in # 1
Next click on the link that comes up
Click on "Number Search"
Enter patent # where requested
Click "SEARCH"
Attached is a link to the Japanese patent which appears to be a patent for Anatabloc:
https://www4.j-platpat.inpit.go.jp/cgi-bin/tran_web_cgi_ejje?u=http://www4.j-platpat.inpit.go.jp/eng/translation/2016090400473373835910262431220784940B2AF8CD178AA0344E3D4E1139FA4
For over 5 years many here have known that being able to moderate excessive inflammation safely is a mighty big deal, but how do we explain that the medical community, the medical media, and wall street have totally ignored the very significant studies that Rock Creek has published in respected journals???
Way to go seek the light!! The Abstract identifies the neural reflex as the "inflammatory reflex".
Wikipedia describes its molecular mechanism as follows:
"Molecular mechanism
The molecular basis of cytokine-inhibiting signals requires the neurotransmitter acetylcholine, and the Alpha-7 nicotinic receptor receptor expressed on cytokine-producing cells.[1] The release of acetylcholine in spleen suppresses the production of TNF and other cytokines which cause damaging inflammation.[2] Signaling in the efferent arc of the inflammatory reflex, termed the "Cholinergic anti-inflammatory pathway," provides a regulatory check on the innate immune system response to invasion and injury. The action potentials arising in the vagus nerve are transmitted to spleen, where a subset of specialized T cells is activated to secrete acetylcholine.[3] The net effect of the reflex is to prevent the damage caused by excessive cytokine production."
This sounds exactly what RCPI has been claiming for the MOA of anatabine.
Anyone have any insight into the latest patent update? It looks like the WORLD PATENT with the TITLE changed from "USE OF ANATABINE TO TREAT INFLAMMATION" to "METHOD OF TREATING INFLAMMATORY LUNG DISEASE".
It also changes the "CLAIMS TARGET" to "INFLAMMATORY LUNG DISEASE" from 'USE OF ANATABINE FOR REDUCING A SYMPTON IN AN INDIVIDUAL OF A DISORDER COMPRISING AN NF-kB-MEDIATED INFLAMMATORY COMPONENT".
In addition it adds "CLAIMS" #6 to #11 with six specific inflammatory lung diseases:
Chronic Lung Disease, Large-cell Undifferentiated Lung Carcinoma, Lung Adenocarcinoma, Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, and Acute Respitory Distress Syndrome.
It has been my opinion that the FDA resisted issuing the original patent because of its claim of treating over 230 diseases and medical conditions. In other words, they wanted more specificity.
If this is the case then we are faced with the question of why Inflammatory Lung Disease?
Could it be that they have someone in that specialty that is willing to go ahead with a joint project once the company proves anatabine's ability to safely knock down inflammation?
Nicobine on YouTube
The included link indicates that 437 subjects have been selected for the Phase III study of Nilvadipine for alzheimer's with 73 more left to go.
Interesting to note that about 10 days ago the figures were 430 and 80.
http://www.nilvad.eu/
Here is the med meeting where RCPI needs to be!!!
http://inflammation2015.org/2015/Home.aspx
The 2015 Boston 12th World Congress on Inflammation Aug. 8-12.
The connections to where RCPI is trying to go are awesome.
Take a close look and enjoy!
A masterful explanation of the significance of this phase I trial.
I had been thinking along these lines and wondering if the unusualness of this phase I study was the reason why it took so long to get the phase I study approved.
If your assessment is anywhere near accurate then Rock Creek will have no problem finding the money it needs to complete the study.
der
You just posted my recent "wish list" to Santa Claus!!!!!!!!
Check link in post# 21549 for news on J&J, Lundbeck, and Wellcome Trust agreement to study immune system and inflammation as causal factors of depression and Alzheimers.
Looks like Roskamp researchers are getting some high class competition:
http://www.wellcome.ac.uk/News/Media-office/Press-releases/2014/WTP058231.htm
How did J&J come up with this radical idea?
http://www.fiercebiotechresearch.com/story/jj-lundbeck-spearhead-rd-consortium-focused-depression-neurodegeneration/2014-12-22
Just noticed that this patent application for the use of anatabine to treat Autism Stress Disorder was assigned to "Jonnie JR".
Will we ever get a study that clearly demonstrates the effectiveness of anatabine!!
As I recall ARCO 31 is the -/- isomer of Nilvadipine, much like the situation with anatabine.
Archer received gov't funding to find an Alzheimer's suppressor which did not have the blood pressure lowering factor of Nilvadipine.
You said,
"Unfortunately, you have no choice: It will be 5-10 years before an Rx version is approved"
I tend to agree with your attitude that I will believe it when I see it, since we only have 4 peer reviewed studies and those were not very in depth.
However, I see nothing anywhere, anyhow that would enable me to guage when an RX could be achieved.
Only time will tell.
Buddhahead, now I understand why DR Alex Roher saw fit to participate in the recent tau phosphorylation study led by DR Paris, and YES, both studies read the same to me!
It's no wonder RCPI burped this morning!!!!!
Very much surprised that there has been little comment about Dr Alex Roher's contribution to this study. His resume is comparable to Dr Mullan's, and his 20 year focus has been on AD and PD. Interesting that he would choose to take part in a study of the mechanism of action of anatabine, since he has not had any previous involvement with it as far as I can determine.
APPOLOGIES TO BUDDHAHEAD. That was message #18896.
Buddhahead has succeded in burying us in NF-kb links while I continued to ponder what his motive was.
Now finally, in message #18897, he delivers the "clincher"!
BRAVO BUDDHAHEAD !!!!!!!!!!!!!!! As an incurable LONG I applaud your effort!!!!!!!!!!!!!!!!!
If one were to listen in one sitting, to everything Dr Mullan had to say about anatabine vs nicotine and varenicline (Chantix) in the March 20 presentation, you just might come to the same conclusion that I did, that SMOKING CESSATION is front and center in Rock Creek’s product development plans.
In speaking about the likely principle targets for development, he said at the 8 minute mark, “It’s much more likely that, WITH PERHAPS THE EXCEPTION OF NICOTEEN ADDICTION, that our 1st principle targets will be peripheral diseases, not CNS diseases”. He is singling out NICOTEEN ADDICTION as a possible target for early development along with some peripheral diseases.
Could be an olive branch to the FDA as they probably would be delighted with an effective smoking cessation product with no significant side effects.
The March 20 presentation was an example of the new openness’ of the company, but there is much that could be going on behind the scenes that we can only guess at.
seek
Much thanks for bringing up the subject as I have been thinking a great deal lately about what would be a great choice for the first disease target
I wouldn't bet on it, but my choice would be Diabetes 2.
There are currently over 300 million with the disease, and the rate of growth of new cases is increasing. The current sales of D-2 meds is 35 billion with 58 billion forcast for 2018.
Another consideration is that the reported results from the Flint study highlighted the impressive results from subjects taking Metformin. Also believe that at least 2 of the major D-2 drugs are going off patent shortly. At any rate IMO Star/Rock Creek is in an incredible position now.
haysaw
In my opinion the good Dr. Mullan speakith not with forked tongue!
He said very clearly for any reasonably intelligent listener to understand that one of the determinants of the choice of disease for Phase II would be aimed at speed to completion of Phase II. Seems like that would not mean using S-(-) or R-(+), since that would eliminate the use of all the experience achieved with RCP006.
You asked, "What does it mean that Roskamp is "taking over" Star? Can anyone shed some light on that?"
It means absolutely nothing except to advance the intent of the changes made at the annual meeting!
When investors look at Rock Creek Pharma we want them to see The Roskamp Institute, not Star Scientific.
Google Herald Tribune Roskamp Star Scientific
I have been reviewing the March 20 video since the 2 hour presentation was a bit much to absorb in one sitting. What has gotten my attention was how much attention was given to tobacco and nicotine.
Couldn't help but wonder if it was a "shot across the bow" to Big Tobacco, like saying "we have a smoking cessation product here which could cripple your business, so lets talk."
Between this 2-hour presentation and today's Star/Roskamp news story, we are seeing the results of a clearly thought out strategy.
Could be that the delay in picking the condition to focus on in the initial IND application is because it will depend on the outcome of negotiations with Big Pharma!
Blzzy. You say, "I understand why they are pulling it...it's not a dietary supplement because by the companies own admission antabine is a drug"
It is difficult to discuss anything when folks are not on the same page. My understanding is that the FDA considers anatabine to not be a food because people ate it without even knowing it was there, nor did they ever eat something because it contained anatabine.
On the other hand the anatabine that Star sells is synthisized containing both the R and S isomers which make up natural anatabine. The drug version is solely the S-(-) isomer which does not occur alone in Nature.
Also, as I have been on antabine since it was available, I have come to believe that anyone who has not been taking it at the recommended dosage for at least 90 days but thinks they know its value or lack thereof is flying a plane without an engine!
Yes, familyman, this is the correct video. The 7 or so minutes he spends talking about anatabine begins at the 4:00 minute mark in video #8. He very clearly notes that anatabine appears to reduce inflammation in the brain, and also reduces Bace1 which leads to the formation of amyloid in the brain.
Everyone watch this Mullan presentation again keeping in mind that Dr Mullan has since accepted the CEO and Board Chairmanship of RCP. To me it says it all.
Yes, the FDA could require the removal of Anatabloc from the marketplace as a condition for receiving IND clearance for anatabine, but Anatabloc could easily be produced in Europe, India, China or wherever legal, and distributed worldwide.
Star has been evolving this business plan for years, but we longtimers just haven't been able to see beyond the "wizard's" curtain!